GHK-Cu in Follicle and Dermal Papilla Research

By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 1 October 2026

GHK-Cu is the tripeptide glycyl-histidyl-lysine complexed with copper, a naturally occurring sequence first isolated from human plasma in the 1970s.^[1] The FDA has not approved GHK-Cu for hair loss or any form of alopecia, no randomized trial of GHK-Cu in human pattern hair loss has been published, and the follicle study most often cited for copper peptides used a structural relative rather than GHK-Cu itself.^[2] This page reports what the literature does contain, in follicle organ culture, in an animal model and in the review literature, and states the regulatory position of the compounded scalp solution and of injectable GHK-Cu, which differ.

It is an evidence reference. The compounded hair and scalp formulations page on this site lists the 1% GHK-Cu scalp solution the 503A pharmacy partner can prepare, and the skin and aesthetics page lists the GHK-Cu creams and serums; neither says what any of them does, and neither does this page.

GHK-Cu is a copper-carrying tripeptide whose literature centers on skin

GHK is glycine, histidine and lysine in that order, a fragment of a larger protein with a mass of roughly 340 daltons as the free peptide.^[3] Its histidine and its terminal amine bind copper(II), and in tissue it exists largely as the complex written GHK-Cu.^[1] A courier who enters certain buildings only with a badge is a fair analogy: the peptide is the courier and the copper is the badge.

Plasma concentrations of the peptide have been reported to fall with age. The 2015 review by Pickart and colleagues in BioMed Research International uses that observation to frame GHK as a natural modulator of skin repair (Fig. 1), and it presents the observation as a motivation for research.^[4]

GHK binds copper(II) with high affinity, and most of what is written about it concerns the copper complex. The 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences summarized the literature that had accumulated since the 1970s: gene-expression studies reporting changes across large sets of human genes, and in vitro and animal work described in the context of wound models, collagen and glycosaminoglycan synthesis, angiogenesis, and anti-inflammatory signaling.^[1] The review is the standard entry point to the field and is cited here as such.

The gene-expression claim traces back to a 2012 Genome Medicine study by Campbell and colleagues. It identified a gene signature of emphysema-related lung tissue destruction and analyzed GHK against it in computational and cell-based work, so the source is a lung study.^[5]

The animal work is where mechanism meets a measured outcome. A 2013 study in Otolaryngology, Head and Neck Surgery examined a topical copper tripeptide complex in an irradiated rat wound model,^[6] and a 2015 study in the Journal of Orthopaedic Research reported a transient outcome effect in a rat ligament reconstruction model.^[7]

Recent work continues in the same tissues. Hu and colleagues examined anti-inflammatory signaling in a zebrafish larvae model in 2026,^[8] and Jeon and colleagues examined a plant-extract and GHK-Cu complex in stimulated keratinocytes the same year.^[9] Mokhtar and colleagues reviewed the aesthetic literature in Aesthetic Surgery Journal in 2026.^[10]

Most of that literature is about skin and wounds rather than hair. The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the breadth of that literature and the FDA’s position on the injectable form; this page confines itself to the follicle.

The best-known follicle study used AHK-Cu, a structural relative

The study most often cited for copper peptides and hair is Pyo and colleagues, published in Archives of Pharmacal Research in 2007.^[2] Using human hair follicles in organ culture and cultured dermal papilla cells, the authors reported that a tripeptide-copper complex elongated the follicles, increased dermal papilla cell proliferation, and reduced markers of programmed cell death in those cells at picomolar to nanomolar concentrations.^[2]

The peptide in that study was AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu that differs in its first residue.^[2] The two peptides share a copper-binding motif and are often discussed together, and the finding is genuinely relevant to the class. It is a finding about AHK-Cu, and citing it for GHK-Cu would substitute one molecule for another in the way the TB-500 evidence page on this site describes for thymosin beta-4.

The animal evidence is a 1993 rodent report on a related copper peptide

Uno and Kurata reported in a 1993 supplement of the Journal of Investigative Dermatology on chemical agents and peptides that affect hair growth.^[11] A copper-binding peptide, PC1031, enlarged follicles on the back skin of fuzzy rats, with an effect the authors compared to topical minoxidil; the paper does not identify PC1031 as GHK-Cu.^[11] The macaque work in the same paper concerned minoxidil, diazoxide and a 5-alpha-reductase inhibitor.^[11] The copper peptide result is a rodent finding from the early 1990s, and it has not been followed by a controlled human trial of GHK-Cu for hair.

Human GHK-Cu evidence sits in skin, cosmetic and wound studies

No randomized controlled trial of GHK-Cu in human pattern hair loss has been published. The human literature on GHK-Cu is concentrated in skin, in cosmetic formulations and in wound studies, and the hair literature is organ culture and animal work. That is the state of the field as of this review, stated once here so the rest of the page can read plainly.

• Organ culture: human follicles and dermal papilla cells, with a tripeptide-copper complex (AHK-Cu) in the 2007 study.^[2]
• Animal model: a related copper-binding peptide, PC1031, in fuzzy rats, reported in 1993.^[11]
• Reviews: the 2015 and 2018 reviews summarize gene-expression, wound and skin literature; hair is a minor part of them.^[1][4]
• Human trials in pattern hair loss: none published for GHK-Cu.

Delivery research explains the pairing with microneedling

A hydrophilic tripeptide-copper complex crosses intact stratum corneum poorly, so delivery is its own research question (Fig. 2).^[12] A 2015 study in Pharmaceutical Research examined microneedle-mediated delivery of copper peptide through skin.^[13] A 2025 review by Ogorek and colleagues in Molecules asked whether permeation of liposomal GHK-Cu can yet be measured reliably.^[12]

Both papers concern getting the molecule where a formulator wants it, and neither measures an effect once it arrives. They are the mechanistic background to pairing copper peptide formulations with microneedling in aesthetic practice.

A cleared microneedling device is cleared to needle, and its clearance covers no particular formulation. The clinic-launch guide on topical application and microneedling, linked below, explains that device line in detail.

The scalp solution and the injectable hold different regulatory positions

No GHK-Cu product is FDA-approved for any hair indication. The 1% scalp solution and the GHK-Cu creams and serums are compounded preparations, prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription and under that board’s oversight, and not evaluated by the FDA for safety, effectiveness or quality.^[14] Cosmetic-grade copper peptide products marketed without disease claims sit in a separate regulatory lane again.

Injectable GHK-Cu is different. FDA placed GHK-Cu for injectable routes of administration in category 2 of its interim policy on bulk drug substances for compounding under section 503A, meaning the agency identified significant safety risks, and that nomination was withdrawn by the nominator in April 2026. FDA now carries the entry under nominations withdrawn and still publishes the rationale it wrote, so the withdrawn route sits in no interim category. GHK-Cu for non-injectable routes, which covers topical preparations, is in category 1 (bulk drug substances under evaluation) on FDA’s 503A list updated 14 May 2026, after a nominator clarified on 5 May 2026 that it had withdrawn only its injectable nomination. Under the interim policy, FDA does not intend to take action against a licensed 503A pharmacy that compounds with a category 1 substance when the policy’s conditions are met, and FDA plans to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027.^[15][16] The FDA’s stated rationale for the withdrawn injectable entry is reproduced here in full:

ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance. The topical formulations the pharmacy partner prepares are listed on the product pages linked below by composition and dating only.

GHK-Cu has a large skin literature and a small hair literature

The gene-expression, wound and animal work is real, and two reviews by the peptide’s principal investigator summarize it. The hair evidence is a related molecule in organ culture and a rodent report on a related copper peptide from the early 1990s.

The two literatures are often presented as one, and reading them separately keeps each claim tied to its tissue. A practice that reads the field this way describes a copper peptide formulation in the terms the organ-culture and animal work allow.